Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Healthtrust
Chinese Patent Office
Dow
Medtronic
Daiichi Sankyo
Johnson and Johnson
UBS
Farmers Insurance

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,759,059

« Back to Dashboard

Which drugs does patent 6,759,059 protect, and when does it expire?

Patent 6,759,059 protects ABSTRAL and is included in one NDA.

This patent has thirty-three patent family members in twenty-four countries.
Summary for Patent: 6,759,059
Title: Fentanyl composition for the treatment of acute pain
Abstract:A pharmaceutical composition for the treatment of acute pain by sublingual administration is described. The composition comprises an essentially water-free, ordered mixture of fentanyl or a pharmaceutically acceptable salt thereof in the form of microparticles which are adhered to the surface of carrier particles which are substantially larger than the particles of fentanyl, and are essentially water-soluble. In a preferred embodiment, the composition also contains a bioadhesion and/or mucoadhesion promoting agent. The invention also relates to the preparation of the composition, and to the use of the composition for the treatment of acute pain.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Uppsala, SE), Lennernas; Hans (Uppsala, SE), Lennernas; Bo (Uddevalla, SE), Hedner; Thomas (Gallsta, SE)
Assignee: Diabact AB (Uppsala, SE)
Application Number:09/787,887
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,759,059
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,759,059

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-001 Jan 7, 2011 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Try a Free Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Try a Free Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-003 Jan 7, 2011 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Try a Free Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-004 Jan 7, 2011 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,759,059

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803239Sep 24, 1998
PCT Information
PCT FiledSeptember 24, 1999PCT Application Number:PCT/SE99/01688
PCT Publication Date:March 30, 2000PCT Publication Number: WO00/16751

International Family Members for US Patent 6,759,059

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 247950 ➤ Try a Free Trial
Australia 6492899 ➤ Try a Free Trial
Australia 764473 ➤ Try a Free Trial
Bulgaria 105380 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Chinese Patent Office
US Department of Justice
Merck
Teva
Argus Health
Mallinckrodt
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.